An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Placebo subcutaneous injections (SC) every 4 weeks through Week 12

CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28

CNTO 6785 200 mg SC every 4 weeks through Week 28

CNTO 6785 100 mg SC every 4 weeks through Week 28

CNTO 6785 50 mg SC every 4 weeks through Week 28

CNTO 6785 15 mg SC every 4 weeks through Week 28

MTX at the same stable dose through Week 32, that participants were receiving prior to screening.